Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Cyprus has seen significant growth in recent years, driven by several factors.
Customer preferences: Patients suffering from rheumatic diseases in Cyprus have shown a growing preference for biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs). This trend is in line with the global market, where biologics have become the preferred treatment option for rheumatic diseases.
Trends in the market: The Anti-Rheumatic Drugs market in Cyprus is expected to continue its growth trajectory, driven by increasing prevalence of rheumatic diseases, rising awareness about the availability of effective treatments, and a growing elderly population. The market is also likely to benefit from the launch of new biologic drugs, which are expected to offer better efficacy and safety profiles compared to existing treatments. However, the market is likely to face challenges from the high cost of biologics and the availability of biosimilars.
Local special circumstances: Cyprus has a high prevalence of rheumatic diseases, with around 2% of the population suffering from rheumatoid arthritis alone. The country also has a well-developed healthcare system, which provides universal coverage and access to treatments. However, the market is relatively small, with a limited number of patients and healthcare providers. This has led to a high level of competition among drug manufacturers, which has resulted in price pressure and a focus on cost-effective treatments.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Cyprus is also influenced by broader macroeconomic factors. The country has a stable economy and a high standard of living, which has resulted in a growing demand for healthcare services. However, the healthcare sector is facing challenges from an aging population and a shortage of healthcare professionals. The government has responded by investing in healthcare infrastructure and increasing funding for healthcare services, which is likely to support the growth of the Anti-Rheumatic Drugs market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
